Explore the potential of monoclonal antibodies in Alzheimer’s treatment, including breakthroughs and challenges in this ...

New 2-year data show the long-term effects of bimekizumab on hidradenitis suppurativa, indicating its potential as a valuable ...

Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for the first authorized use of an ...

Prothena (NASDAQ:PRTA – Free Report) had its price target boosted by Oppenheimer from $58.00 to $62.00 in a report published on Friday,Benzinga reports. They currently have an outperform rating on the ...

Alloy Therapeutics enters multi-year collaboration with Pfizer to develop new antibody discovery platform: Boston, Massachusetts Thursday, February 13, 2025, 13:00 Hrs [IST] Alloy ...

New Delhi: Intas Pharmaceuticals has got approval from the Subject Expert Committee (SEC) functional under the Central Drug ...

StockNews.com assumed coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT – Free Report) in a research note released on Friday. The firm issued a hold rating on the stock. Oncternal Therapeutics ...

After an apparent accidental early release, Pfizer has revealed phase 1 data showing its investigational candidate, alongside ...

The FDA has approved the sBLA for once every 4 weeks lecanemab-irmb (Leqembi®) intravenous maintenance dosing.

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today issued their quarterly report containing Leqembi sales for the fourth quarter 2024 (third quarter ...